Hope for PDCD Foundation

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2022

Legal Domicile

Phone

7076169750

Tax Period

2024-01-01 to 2024-12-31

Hope for PDCD Foundation, founded in 2022, is a small nonprofit in the Medical Research sector that reported $330K in total revenue in fiscal year 2024. Revenue fell 22% from the prior year — a significant decline worth monitoring. The organization ran a surplus of $152K, a strong 46% operating margin.

Mission

Support and fund the development of life-saving treatment for patients with pyruvate dehydrogenase complex deficiency and related genetic diseases The activities of the foundation include providing grant funding to hospitals and medical research facilities which are conducting medical research for understanding and treatment of this condition The foundation also provides funding to individuals that assist with early patient identification through newborn screening for this condition.

Program Service Accomplishments

Program 1

Expenses: $172,385 Revenue: $0

The foundation makes annual grants to tax exempt medical research facilities which conduct research in a variety of fields related to PDCD which will further the foundations mission of expanding the understanding and treatment of this condition This was a payment for University of Texas Southwestern UTSW Medical Facility as part of OTD Contract SRA202302-0021 to conduct gene therapy research for PDHA1 genetic mutations causing Pyruvate Dehydrogenase Complex Deficiency including but not limited to synthesis of vector design and development of a mouse colony and AAV vector manufacture

Program 2

Expenses: $5,000 Revenue: $0

Childrens Hospital of Philadelphia Activity Assay focuses on optimizing the detection of acetyl-CoA which is crucial for PDCD within the mass spectrometry instruments sensitivity range. The study...

Childrens Hospital of Philadelphia Activity Assay focuses on optimizing the detection of acetyl-CoA which is crucial for PDCD within the mass spectrometry instruments sensitivity range. The study compares media versus cells with reduced interference. Various PDCD lines mild vs. severe will be examined and contrasted. Additionally PDCD will be compared with other tricarboxylic cycle deficiencies and ETC defects to ensure distinguishability.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $329,977

Program Service Revenue $0

Investment Income $0

Other Revenue $454

TOTAL REVENUE $330,431

Expense Breakdown

Grants Paid $177,385

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $177,385

Other Expenses $1,006

TOTAL EXPENSES $178,391

Year-over-Year Comparison

	2024	2023	Change
Revenue	$330,431	$426,280	-0.2%
Expenses	$178,391	$175,725	+0.0%
Net Income	$152,040	$250,555	-0.4%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Frances Pimentel	Chief Executive Officer	10.00	Officer Director	$0	$0	$0
Jon Pimentel	Chief Financial Officer	5.00	Officer Director	$0	$0	$0
Kimberlee Muenzer	Secretary	1.00	Officer Director	$0	$0	$0
Kim Higbee	Director	1.00	Director	$0	$0	$0
Katy Cairo	Director	1.00	Director	$0	$0	$0
Patricia Medlen	Director	1.00	Director	$0	$0	$0
Carly Tasiopoulos	Director	1.00	Director	$0	$0	$0
Chris Tasiopoulos	Director	1.00	Director	$0	$0	$0
Nikki Kulovitz	Director	1.00	Director	$0	$0	$0
Molly Naccarato	Director	1.00	Director	$0	$0	$0
Brandy Jackson	Director	1.00	Director	$0	$0	$0
Layna O'Connor	Director	1.00	Director	$0	$0	$0
Natasha Baril	Director	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$330,431	$178,391	$557,893	$152,040
2023	$426,280	$175,725	$405,853	$250,555
2022	$208,000	$52,702	$155,298	$155,298